Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029279 | 0.82 | PDE4A (0.59) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL29440119 | 0.77 | PDE4A (0.54) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL142851 | 0.77 | PDE4D (0.54) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL6814857 | 0.77 | PDE4D (0.54) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL4160646 | 0.77 | PDE4A (0.61) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL31614784 | 0.76 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL21079189 | 0.75 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL7362652 | 0.75 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CKDM4E | |
| SCHEMBL30555836 | 0.74 | CA12 (0.67) | PDE4APDE4DPDE4BPDE4CPOLB | |
| SCHEMBL563069 | 0.74 | CA12 (0.67) | PDE4APDE4DPDE4BPDE4CPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107162928-B | Halogenated analogs of anti-fibrotic agents | 塞尔塔医疗有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3045170-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| EP-3045170-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2016-07-20 | — | — | EP | disclosed |
| EP-2220028-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2016-03-09 | — | — | EP | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
| EP-2220028-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079692-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | PDE4A 1436/4885PDE4D 1529/4885PDE4B 1131/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | PDE4A 1436/4885PDE4D 1529/4885PDE4B 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.